Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
Open Access
- 15 August 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (16) , 8884
Abstract
Metformin is a widely employed drug in type 2 diabetes. In addition to warranting good short- and long-term glycemic control, metformin displays many intriguing properties as protection against cardiovascular and neurodegenerative diseases, anti-tumorigenic and longevity promotion. In addition to being a low-cost drug, metformin is generally well tolerated. However, despite the enthusiastic drive to aliment these novel studies, many contradictory results suggest the importance of better elucidating the complexity of metformin action in different tissues/cells to establish its possible employment in neurodegenerative diseases. This review summarises recent data identifying lysosomal-dependent processes and lysosomal targets, such as endosomal Na+/H+ exchangers, presenilin enhancer 2 (PEN2), the lysosomal pathway leading to AMP-activated protein kinase (AMPK) activation, and the transcription factor EB (TFEB), modulated by metformin. Lysosomal dysfunctions resulting in autophagic and lysosomal acidification and biogenesis impairment appear to be hallmarks of many inherited and acquired neurodegenerative diseases. Lysosomes are not yet seen as a sort of cellular dump but are crucial in determining key signalling paths and processes involved in the clearance of aggregated proteins. Thus, the possibility of pharmacologically modulating them deserves great interest. Despite the potentiality of metformin in this context, many additional important issues, such as dosing, should be addressed in the future.Keywords
This publication has 122 references indexed in Scilit:
- Autophagy and exosomes; inter-connected maestros in Alzheimer’s diseaseInflammopharmacology, 2024
- Clearance of β‐amyloid mediated by autophagy is enhanced by MTORC1 inhibition but not AMPK activation in APP/PSEN1 astrocytesGlia, 2023
- Do oral antidiabetic medications alter the risk of Parkinson’s disease? An updated systematic review and meta-analysisNeurological Sciences, 2023
- Modulation of autophagy, apoptosis and oxidative stress: a clue for repurposing metformin in photoagingInflammopharmacology, 2022
- Metformin prevents p-tau and amyloid plaque deposition and memory impairment in diabetic miceExperimental Brain Research, 2021
- Metformin: historical overviewDiabetologia, 2017
- Regulation of organelle function by metforminIUBMB Life, 2017
- Metformin improves anxiety-like behaviors through AMPK-dependent regulation of autophagy following transient forebrain ischemiaMetabolic Brain Disease, 2015
- Autophagy: cellular and molecular mechanismsThe Journal of Pathology, 2010
- Cholesterol in Niemann–Pick Type C disease2010